The right drug, wrong patients

Aylesbury High School honours former pupil Dr Layla Hosseini-Gerami.

Ignota Labs Acquires Kronos’s Clinical Pipeline

Predicting human biology in the era of foundational models

Discovery is not the issue

Ignota Labs sponsors Next Tech Fest 2025

2025 Cross-Sector Experience Awards announced

Best Practices for Applying AI in Small Molecule Toxicology

Fixing failed drugs - AI solutions for toxicity in drug discovery Part 3

Ignota Labs CSO Jordan Lane becomes an enterprise fellow at Clare Hall

Fixing failed drugs - AI solutions for toxicity in drug discovery Part 2

Fixing failed drugs - AI solutions for toxicity in drug discovery Part 1

Dr Jordan Lane appointed as Industry and Enterprise Fellow at Clare Hall, University of Cambridge

Honour for CSO maintains upward trajectory for Ignota Labs

Generative AI for Drug Discovery

Turning failing drugs into hope for patients

Biotech’s AI-Q: Smarter Strategies for Success

Giving Drugs a Second Chance with AI

Machine Learning for Toxicity Prediction Using Chemical Structures: Pillars for Success in the Real World

From failures to first-in-class: Using AI to rescue and reposition assets

Start-up of the Week

Flipping Drugs - From PhD to CDSO

Dr. Layla Hosseini-Gerami named to Forbes 30 under 30

Alumni Stories and Successes: An Experimental Spirit

AI For Drug Discovery & Development

This startup is using AI to give failed drugs a second chance

How biotechs are using AI to rescue failed drugs

IWD 2025: TFN spotlights on 12 women reshaping the future of tech in Europe

Who or what called you to lead?

Ignota Labs Raises USD $6.9M Seed Funding to Turn Around Failed Drugs

Dr Layla Hosseini-Gerami invited to 10 Downing Street

Dr Layla Hosseini-Gerami named as one of Innovate UK’s trailblazing women innovators to watch in 2025

Ignota Labs secures Sanofi’s prestigious iDEA-Tech Award

Advancing predictive toxicology: overcoming hurdles and shaping the future

An interview with our CEO Sam Windsor

Ignota Labs In-Licenses First Proprietary Asset: Pioneering PDE9A Inhibitor Set to Transform Multi-Action Therapeutics

Why drugs fail

Rescuing failed drug projects

Ignota Labs accepted for the 2024 cohort of TechBio Boost

Improved Detection of Drug-Induced Liver Injury

Ignota Labs winners at Royal Society of Chemistry’s Emerging Technologies Competition 2024

Ignota Labs named Milner Therapeutics Institute affiliated company

Jordan Lane

OBN Awards Nomination

A day in the life of a Chief Science Officer and Cofounder of Ignota Labs

Using Explainable AI To Ensure Drug Discovery Safety

Drug Discovery: Breaking Barriers

Ignota Labs named winners of ELRIG 2024 Innovation Award

20 Pharma Startups to Watch in 2025

Ignota Labs appoints Didier Landais as Non-Executive Director

Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank

Safety first for Ignota Labs as it relocates AI-Pharma proposition to new Cambridge HQ

Introducing Ignota Labs with cofounder Dr Layla Hosseini-Gerami

11 drug discovery startups to watch, according to VCs

Why ChatGPT and the like will never gain acceptance in drug discovery

Revolutionising Drug Discovery with In Silico Toxicology Screening